NKI-AVL
Amsterdam, 1066CX, Netherlands
Location status: Recruiting
Location contact
Henry Zijlmans, MD, PhD
PRINCIPAL_INVESTIGATOR
NKI-AVL Zijlmans, MD, PhD
CONTACT
NCT Number: NCT04192253
Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive thereby diminishing the chance for morbidity.
Interested in participating?
Request Info18 year and older
Female
Interventional
Phase 2
Amsterdam, 1066CX, Netherlands
Location status: Recruiting
Henry Zijlmans, MD, PhD
PRINCIPAL_INVESTIGATOR
NKI-AVL Zijlmans, MD, PhD
CONTACT
Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive, thereby diminishing the chance for morbidity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
Time frame: 18 weeks
tumour size change by neoadjuvant chemotherapy measured by RECIST 1.1
Time frame: 21 weeks
number of patients were surgery can be reduced after the neo-adjuvant chemotherapy
Time frame: 21 weeks
Chemotherapy related morbidity measured by reported adverse events
Time frame: 5 years after treatment
overall survival
Contact information is provided by the study sponsor or research team.
The Netherlands Cancer Institute
Other
Acronym: VULCANize
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.